# US 2022/0008510 A1 · Manipulation of meningeal lymphatic vasculature for brain and cns tumor therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0008510 A1
- Document ID: US20220008510A1
- Status: Published application
- Kind: A1
- Application number: 17/294,018
- Filed: 2019-11-15
- Published: 2022-01-13
- Earliest claimed: 2018-11-16
- Assignees: Yale University
- Applicants: Yale University
- Inventors: Akiko IWASAKI; Jean-Leon THOMAS; Eric SONG
- Web page: https://patentgrep.com/patent/US20220008510A1

## CPC

- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61K 39/39541: {against normal tissues, cells}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61P 35/04: specific for metastasis
- A61P 37/04: Immunostimulants
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C12N 15/86: Viral vectors
- A01K 2207/12: Animals modified by administration of exogenous cells
- A01K 2227/105: Murine
- A01K 2267/0331: Animal model for proliferative diseases
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A method of inducing lymphangiogenesis in the brain or central nervous system of a subject is provided in which an effective amount of a lymphangiogenesis inducer is administered. A method of inducing lymphangiogenesis in a tumor in the brain or central nervous system of a subject is provided in which an effective amount of a lymphangiogenesis inducer is administered. A method of treating a cancer of the brain or central nervous system is also provided in which an effective amount of a lymphangiogenesis inducer is administered. An example of a lymphangiogenesis inducer is VEGFC. The lymphangiogenesis inducer can be in the form of a protein or a polynucleotide encoding the protein, such as an mRNA or AAV. The lymphangiogenesis inducer can be administered to the cistemamagna or directly into the lymphatic system. An immunotherapeutic agent, such as a checkpoint inhibitor, may also be administered.

## Claims

### Claim 1

A method of inducing lymphangiogenesis in the brain or central nervous system of a subject in need thereof, the method comprising administering to the subject an effective amount of a lymphangiogenesis inducer.

### Claim 2

A method of inducing lymphangiogenesis in a tumor in the brain or central nervous system of a subject in need thereof, the method comprising administering to the subject an effective amount of a lymphangiogenesis inducer.

### Claim 3

A method of treating a cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a lymphangiogenesis inducer, wherein the cancer is in the brain or the central nervous system of the subject.

### Claim 4 (depends on 3)

The method of claim 3, further comprising administering an immunotherapeutic agent.

### Claim 5 (depends on 3, 4)

The method of claim 3 or claim 4, wherein the method does not comprise administering a tumor-specific antigen to the subject.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the lymphangiogenesis inducer is VEGFA, VEGFB, VEGFC or VEGFD.

### Claim 7 (depends on 6)

The method of claim 6, wherein the lymphangiogenesis inducer is VEGFC.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the lymphangiogenesis inducer is administered as a protein.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the lymphangiogenesis inducer is administered as a polynucleotide molecule encoding the lymphangiogenesis inducer protein.

### Claim 10 (depends on 9)

The method of claim 9, wherein the polynucleotide molecule encoding the lymphangiogenesis inducer is a mRNA.

### Claim 11 (depends on 9)

The method of claim 9, wherein the polynucleotide molecule encoding the lymphangiogenesis inducer is comprised within a viral vector.

### Claim 12 (depends on 9, 10, 11)

The method of any one of claims 9-11, wherein the polynucleotide molecule encoding the lymphangiogenesis inducer is comprised within, attached to, or electrostatically bound to a liposome, a nanoparticle or a polymer.

### Claim 13 (depends on 12)

The method of claim 12, wherein the nanoparticle is a nanosphere.

### Claim 14 (depends on 12)

The method of claim 12, wherein the polymer is dextran, poly (amine-co-ester), poly(beta-amino-ester), polyethylenimine, poly-L-Lysine, polyethylene glycol, or dendrimers.

### Claim 15 (depends on 9, 11)

The method of claim 9 or claim 11, wherein the polynucleotide molecule encoding the lymphangiogenesis inducer is comprised within a recombinant viral particle or within a VLP.

### Claim 16 (depends on 15)

The method of claim 15, wherein the recombinant viral particle is derived from a herpes virus, a cytomegalovirus, a poliovirus, an alphavirus, a vaccinia virus, a rabies virus, an adeno-associated virus (AAV), a retrovirus or an adenovirus.

### Claim 17 (depends on 16)

The method of claim 16, wherein the retrovirus is a lentivirus.

### Claim 18 (depends on 16)

The method of claim 16, wherein the recombinant viral particle is derived from an adeno-associated virus (AAV).

### Claim 19 (depends on 18)

The method of claim 18, wherein the AAV is AAV2, AAV5 or AAV9.

### Claim 20 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 9-19, wherein the polynucleotide molecule encoding the lymphangiogenesis inducer comprises a modified nucleotide such as 5-methyl-cytosine and pseudo-uridine substitutions that can increase stability, decrease deamination, decrease nuclease activity, decrease innate recognition, or increase translation efficiency of the polynucleotide molecule.

### Claim 21 (depends on 20)

The method of claim 20, wherein the modified nucleotide is a 5-methyl-cytosine or a pseudo-uridine.

### Claim 22 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 9-21, wherein the polynucleotide molecule encoding the lymphangiogenesis inducer comprises a 5′ cap.

### Claim 23 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 4-22, wherein the immunotherapeutic agent is an immune checkpoint inhibitor.

### Claim 24 (depends on 23)

The method of claim 23, wherein the immune checkpoint inhibitor targets PD-1, PD-L1, CTLA-4, TIGIT, TIM-3, LAG-3, BTLA, GITR, 4-1BB, or Ox-40.

### Claim 25 (depends on 24)

The method of claim 24, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, an anti-TIGIT antibody, an anti-TIM-3 antibody, an anti-LAG-3 antibody, an anti-BLTA antibody, an anti-GITR antibody, an anti-4-1BB antibody or an anti-Ox-40 antibody.

### Claim 26 (depends on 25)

The method of claim 25, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.

### Claim 27 (depends on 25)

The method of claim 25, wherein the immune checkpoint inhibitor is an anti-4-1BB antibody.

### Claim 28 (depends on 25)

The method of claim 25, wherein the immune checkpoint inhibitor is an anti-TIM3 antibody.

### Claim 29 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 4-22, wherein the immunotherapeutic agent comprises an anti-PD-1 antibody and an anti-4-1BB antibody.

### Claim 30 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 4-22, wherein the immunotherapeutic agent comprises an anti-PD-1 antibody and an anti-TIM3 antibody.

### Claim 31 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 4-30, wherein the lymphangiogenesis inducer and the immunotherapeutic agent are administered conjointly.

### Claim 32 (depends on 31)

The method of claim 31, wherein the lymphangiogenesis inducer and the immunotherapeutic agent are administered in the same composition.

### Claim 33 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 4-30, wherein the lymphangiogenesis inducer and the immunotherapeutic agent are administered sequentially.

### Claim 34 (depends on 33)

The method of claim 33, wherein the lymphangiogenesis inducer is administered prior to administering the immunotherapeutic agent.

### Claim 35 (depends on 34)

The method of claim 34, wherein the lymphangiogenesis inducer is a recombinant AAV vector encoding VEGF, which is administered about 4-8 weeks prior to administering the immunotherapeutic agent.

### Claim 36 (depends on 34)

The method of claim 34, wherein the lymphangiogenesis inducer is a mRNA encoding VEGF, which is administered about 2-6 hours prior to administering the immunotherapeutic agent.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 1-36, wherein the lymphangiogenesis inducer is administered intrathecally, intratumorally, intracistemally, or systemically.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 1-37, wherein the immunotherapeutic agent is administered systemically.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 1-36, wherein the immunotherapeutic agent is administered intrathecally.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 1-36, wherein the immunotherapeutic agent is administered to the cisterna magna or directly into the lymphatic system.

### Claim 41 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any one of claims 3-40, further comprising administering an additional anti-cancer treatment to the subject.

### Claim 42 (depends on 41)

The method of claim 41, wherein the additional anti-cancer treatment is selected from surgery, radiation therapy, administration of a chemotherapeutic agent, an immunotherapy, and any combinations thereof

### Claim 43 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 3-42, wherein the cancer is selected from glioma, ependymoma, subependymoma, primitive neuroectodermal tumor, ganglioglioma, Schwannoma, germinoma, craniopharyngioma, meningioma, CNS lymphoma, pineal tumor, and rhabdoid tumor.

### Claim 44 (depends on 43)

The method of claim 43, where glioma is selected from astrocytoma, glioblastoma, oligodendroglioma, brain stem glioma, juvenile pilocytic astrocytoma, and optic nerve glioma.

### Claim 45 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 3-44, wherein the cancer is glioblastoma.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The method of any one of claims 1-45, wherein the subject is a human patient.

### Claim 47 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 3-46, wherein the method is effective to treat the cancer in the subject.

### Claim 48 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 3-46, wherein the method is effective to reduce the volume of a tumor in the brain or the central nervous system of the subject.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 1-46, wherein the method is effective to induce lymphangiogenesis in the tumor in the brain or the central nervous system of the subject.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 1-46, wherein the method is effective to prime T cells against the tumor in the brain or central nervous system of the subject.

### Claim 51

A pharmaceutical composition comprising a lymphangiogenesis inducer and an immunotherapeutic agent.

### Claim 52 (depends on 51)

The composition of claim 51, wherein the lymphangiogenesis inducer is VEGFA, VEGFB, VEGFC or VEGFD.

### Claim 53 (depends on 52)

The composition of claim 52, wherein the lymphangiogenesis inducer is VEGFC.

### Claim 54 (depends on 51, 52)

The composition of claim 51 or claim 52, wherein the lymphangiogenesis inducer is a protein.

### Claim 55 (depends on 51, 52, 53, 54)

The composition of any one of claims 51-54, wherein the lymphangiogenesis inducer is a polynucleotide molecule encoding the lymphangiogenesis inducer protein.

### Claim 56 (depends on 55)

The composition of claim 55, wherein the polynucleotide molecule encoding the lymphangiogenesis inducer is a mRNA.

### Claim 57 (depends on 55)

The composition of claim 55, wherein the polynucleotide molecule encoding the lymphangiogenesis inducer is comprised within a viral vector.

### Claim 58 (depends on 51, 52, 53, 54, 55, 56, 57)

The composition of any one of claims 51-57, wherein the polynucleotide molecule encoding the lymphangiogenesis inducer is comprised within, attached to, or electrostatically bound to a liposome, a nanoparticle or a polymer.

### Claim 59 (depends on 58)

The composition of claim 58, wherein the nanoparticle is a nanosphere.

### Claim 60 (depends on 58)

The composition of claim 58, wherein the polymer is dextran, poly (amine-co-ester), poly(beta-amino-ester), polyethylenimine, poly-L-Lysine, polyethylene glycol, or dendrimers.

### Claim 61 (depends on 55, 57)

The composition of claim 55 or claim 57, wherein the polynucleotide molecule encoding the lymphangiogenesis inducer is comprised within a recombinant viral particle or within a VLP.

### Claim 62 (depends on 61)

The composition of claim 61, wherein the recombinant viral particle is derived from a herpes virus, a cytomegalovirus, a poliovirus, an alphavirus, a vaccinia virus, a rabies virus, an adeno-associated virus (AAV), a retrovirus or an adenovirus.

### Claim 63 (depends on 62)

The composition of claim 62, wherein the retrovirus is a lentivirus.

### Claim 64 (depends on 62)

The composition of claim 62, wherein the recombinant viral particle is derived from an adeno-associated virus (AAV).

### Claim 65 (depends on 64)

The composition of claim 64, wherein the AAV is AAV2, AAV5 or AAV9.

### Claim 66 (depends on 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The composition of any one of claims 55-65, wherein the polynucleotide molecule encoding the lymphangiogenesis inducer comprises a modified nucleotide such as 5-methyl-cytosine and pseudo-uridine substitutions that can increase stability, decrease deamination, decrease nuclease activity, decrease innate recognition, or increase translation efficiency of the polynucleotide molecule.

### Claim 67 (depends on 66)

The composition of claim 66, wherein the modified nucleotide is a 5-methyl-cytosine or a pseudo-uridine.

### Claim 68 (depends on 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The composition of any one of claims 55-67, wherein the polynucleotide molecule encoding the lymphangiogenesis inducer comprises a 5′ cap.

### Claim 69 (depends on 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The composition of any one of claims 51-68, wherein the immunotherapeutic agent is an immune checkpoint inhibitor.

### Claim 70 (depends on 69)

The composition of claim 69, wherein the immune checkpoint inhibitor targets PD-1, PD-L1, CTLA-4, TIGIT, TIM-3, LAG-3, BTLA, GITR, 4-1BB, or Ox-40.

### Claim 71 (depends on 70)

The composition of claim 70, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, an anti-TIGIT antibody, an anti-TIM-3 antibody, an anti-LAG-3 antibody, an anti-BLTA antibody, an anti-GITR antibody, an anti-4-1BB antibody or an anti-Ox-40 antibody.

### Claim 72 (depends on 71)

The composition of claim 71, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.

### Claim 73 (depends on 71)

The composition of claim 71, wherein the immune checkpoint inhibitor is an anti-4-1BB antibody.

### Claim 74 (depends on 71)

The composition of claim 71, wherein the immune checkpoint inhibitor is an anti-TIM3 antibody.

### Claim 75 (depends on 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The composition of any one of claims 51-68, wherein the immunotherapeutic agent comprises an anti-PD-1 antibody and an anti-4-1 BB antibody.

### Claim 76 (depends on 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The composition of any one of claims 51-68, wherein the immunotherapeutic agent comprises an anti-PD-1 antibody and an anti-TIM3 antibody.

### Claim 77 (depends on 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The composition of any one of claims 55-76, wherein the composition is formulated for intrathecal administration.

### Claim 78 (depends on 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The composition of any one of claims 55-76, wherein the composition is formulated for intratumoral administration.

### Claim 79 (depends on 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The composition of any one of claims 55-76, wherein the composition is formulated for systemic administration.

### Claim 80 (depends on 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The composition of any one of claims 55-76, wherein the composition is formulated for intracisternal administration.
